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ABSTRACT
Metabolic reprogramming is a feature of neoplasia and tumor growth. Sirtuin 
1 (SIRT1) is a lysine deacetylase of multiple targets including metabolic regulators 
such as p53. SIRT1 regulates metaplasia in the pancreas. Nevertheless, it is unclear 
if SIRT1 affects the development of neoplastic lesions and whether metabolic gene 
expression is altered.
To assess neoplastic lesion development, mice with a pancreas-specific loss of 
Sirt1 (Pdx1-Cre;Sirt1-lox) were bred into a KrasG12D mutant background (KC) that 
predisposes to the development of pancreatic intra-epithelial neoplasia (PanIN) and 
ductal adenocarcinoma (PDAC). Similar grade PanIN lesions developed in KC and 
KC;Sirt1-lox mice but specifically early mucinous PanINs occupied 40% less area in 
the KC;Sirt1-lox line, attributed to reduced proliferation. This was accompanied by 
reduced expression of proteins in the glycolysis pathway, such as GLUT1 and GAPDH.
The stimulatory effect of SIRT1 on proliferation and glycolysis gene expression 
was confirmed in a human PDAC cell line. In resected PDAC samples, higher 
proliferation and expression of glycolysis genes correlated with poor patient survival. 
SIRT1 expression per se was not prognostic but low expression of Cell Cycle and 
Apoptosis Regulator 2 (CCAR2), a reported SIRT1 inhibitor, corresponded to poor 
patient survival. 
These findings open perspectives for novel targeted therapies in pancreatic cancer.
INTRODUCTION
The incidence of pancreatic cancer is on the rise, 
being projected to become the second cause of cancer-
related deaths by 2030 [1]. Patients diagnosed with 
pancreatic ductal adenocarcinoma (PDAC), the most 
common form of pancreatic cancer, still face a very 
poor outcome with a 5-year survival of 5–7%. Surgical 
resection offers the best chance of cure; however most 
patients present with locally advanced or metastatic 
disease and are therefore ineligible for surgery [2]. 
Novel combination therapies such as nab-paclitaxel 
with gemcitabine or FOLFIRINOX have improved 
patient outcomes but improvements are small and toxicity 
is an issue [2].
Sirtuin1 (SIRT1) inhibitors have shown promising 
results in preclinical models of PDAC (reviewed in [3]). 
SIRT1 is an evolutionary conserved protein that senses 
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NAD+ and resides in the nucleus or the cytoplasm 
where it can deacetylate a panel of proteins that regulate 
inflammation, lifespan and metabolic homeostasis, 
among many other processes (reviewed in [3–9]). The 
tumor suppressor p53 is the best studied protein that is 
deacetylated and inactivated by SIRT1 [10]. SIRT1 itself 
is regulated by Cell Cycle and Apoptosis Regulator 2 
(CCAR2), an endogenous inhibitor of SIRT1’s deacetylase 
activity in various organs, including in the pancreas [11]. 
Not only by its consumption of NAD+ does 
SIRT1 function as an energy sensor, it also mediates 
metabolic effects in liver, skeletal muscle, heart and 
adipocytes by directly deacetylating proteins that regulate 
gluconeogenesis, fatty acid metabolism and glycolysis [12]. 
Through effects on Phosphoglycerate 1 (PGAM1) and 
peroxisome proliferator-activated receptor alpha coactivator 
1 alpha (PGC1a), SIRT1 was found a negative regulator 
of glycolysis in liver and skeletal muscle [12]. Contrary, 
through inactivation of p53 SIRT1 can stimulate glycolysis 
[13], underscoring the dependency on the context.
The biological functions of SIRT1 in PDAC are still 
poorly understood. We recently reported a role for SIRT1 
in the development of pancreatic acinar-ductal metaplasia, 
a process that occurs in acute and chronic pancreatitis and 
may give rise to neoplastic lesions [14]. We now sought 
to explore if SIRT1 also impacts the development of (pre)
tumoral lesions. In addition, we analyzed a potential 
metabolic regulation by SIRT1 in pancreatic lesions.
RESULTS
Sirt1 promotes the proliferation of mucinous 
intraepithelial neoplastic lesions in the murine 
pancreas
Mice with an activating mutation in Kras 
(lox-STOP-lox KrasG12D) [15] that is specifically targeted 
to the pancreas by a Pdx1-Cre driver (abbreviated KC 
mice) were crossed with a mouse line in which the exon 
4 of Sirt1 is flanked by loxP sites to obtain homozygous 
Sirt1-deficient KC mice (KC;Sirt1-lox) [14, 16]. Only very 
low expression of the mutant form of SIRT1 protein is 
found in the pancreas of the KC;Sirt1-lox animals (Figure 
1A and [16]). Cheng et al. have previously shown that 
the resulting short mutant form of SIRT1 lacks SIRT1 
deacetylation activity, resulting in a phenotype similar to 
a full SIRT1 knock out [17]. KC;Sirt1-lox animals were 
sacrificed at 6 and 12 months of age, in parallel with a 
cohort of KC control mice. We observed that in the mice 
that had not been culled earlier because of reaching ethical 
endpoints (due to PDAC, another tumor or unknown 
cause), PanIN1-3 lesions progressively developed at 6 
and 12 months of age (Figure 1B). The progression of the 
lesions scored by the grade of the PanINs did not differ 
when comparing KC controls with KC;Sirt1-lox mice 
(Figure 1B). 
To evaluate the lesion burden, we quantified the area 
occupied by PanIN lesions using two different methods: 
Keratin 19 (Krt19) immunohistochemistry and Alcian 
Blue staining of mucinous lesions. The relative area of 
Krt19 positive lesions presented no differences between 
KC controls and KC;Sirt1-lox mice (Supplementary 
Figure S1). However, the area of mucinous early PanINs, 
measured by the percentage of Alcian Blue–positive, 
was significantly lower in the KC;Sirt1-lox mice 
(1.6 ± 0.2% versus 2.6 ± 0.4% area, n = 9–11, P < 0.05, 
Figure 1C, 1D).
The reduced area occupied by mucinous neoplastic 
lesions was attributed to lower proliferation, measured 
by Ki67 immunohistochemistry (IHC) in the KC;Sirt1-
lox background compared to KC controls (60 ± 13 
versus 104 ± 13 counts of Ki67 positive cells per field, 
n = 9–13, P < 0.05, Figure 1E, 1F). There was no 
statistically significant difference in the proliferation of 
the neighboring stroma. In addition, all mice analyzed 
only showed very low apoptosis in the lesions, detected 
by cleaved caspase-3 staining (not shown). Pancreata from 
Kras wild type Pdx1-Cre;Sirt1-lox mice did not show 
alterations in the proliferation of any cell type (acinar, 
duct, islets or stroma) when compared with Pdx1-Cre 
controls (Supplementary Figure S2), suggesting the effect 
on proliferation is specific for the early lesions in the Kras 
mutant background. 
In conclusion, SIRT1 is dispensable for pancreatic 
lesion development, does not affect the proliferation of 
normal pancreatic tissue but specifically stimulates the 
growth of early mucinous PanIN lesions.
SIRT1 regulates the expression of glycolysis 
genes in mouse pancreas
Ample evidence is available that proliferation 
of (pancreatic) tumor cells is enabled by an increased 
rate of intracellular glucose import and a higher rate of 
aerobic glycolysis (referred to as the Warburg effect) 
[18]. Moreover, SIRT1 is a known metabolic regulator 
and deacetylates several proteins that play critical 
roles in glycolysis such as p53 [13] and MYC [19]. 
Therefore, we verified if SIRT1’s effect on proliferation 
of the pancreatic lesions involved changes in glycolysis 
genes.
We used our SIRT1-deficient mouse model to verify 
a regulation of glycolysis proteins by SIRT1 in pancreatic 
lesions in vivo. When comparing immunostainings in 
the PanIN lesions in KC;Sirt1-lox versus KC controls, 
we found a weaker staining for GLUT1 (Glucose 
transporter 1), GAPDH (Glyceraldehyde 3-phosphate 
dehydrogenase) and PKM2 (Pyruvate kinase isozyme m2) 
and slightly weaker HK2 (Hexokinase 2) (Figure 2).
In conclusion, SIRT1 stimulates the expression of 
glycolysis genes in mouse PanIN lesions.
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SIRT1 stimulates proliferation and glycolysis 
gene expression in human PDAC
Complementary to our in vivo observations in the 
mice, we down-regulated SIRT1 gene expression using 
siRNA in a human pancreatic tumor cell line. Effective 
knock down of SIRT1 in Panc1 cells was demonstrated by 
reduced SIRT1 protein in Western Blotting analysis, along 
with increased acetylation of SIRT1’s best-characterized 
substrate p53 [10] and downstream upregulation of p21, 
a known p53 target gene (Figure 3A and Supplementary 
Figure S3). We found that knock down of SIRT1 impaired 
the proliferation of the PDAC cells, an extension of 
previous reports [14, 20] (Figure  3B). The cells treated 
with siRNA for SIRT1 had a consistent reduction in 
the mRNA of SIRT1, GLUT1 (Glucose transporter 1), 
GAPDH, PKM2 and LDHA (Lactate dehydrogenase A) 
(Figure 3C).
High proliferation, high glycolysis gene 
expression and low expression of a SIRT1 
inhibitor corresponds to the poorest patient 
survival outcomes
We analyzed if SIRT1 expression was prognostic in 
human PDAC, using a patient cohort of treatment-naive 
early stage I and II resected PDAC (n = 104) [21]. Staining 
for SIRT1 protein expression (nuclear, cytoplasmic or 
total) in the PDAC cells, following the protocol we had 
previously optimized in another smaller cohort [14], did 
not directly correlate with survival outcome (Figure 4A 
and not shown). We verified if instead, expression of the 
Figure 1: Pancreatic lesions in KC and homozygous KC;Sirt1-lox mice. (A) Western Blot analysis of Sirt1, Ccar2 and Beta-
Actin (B-Actin) protein expression in whole pancreas tissue, n = 4 per group. (B) Percentage of animals with the highest lesion in pancreas 
tissue sections that were classified as normal, PanIN 1,2 or 3. n = 20 KC;Sirt1-lox and n = 27 KC at 6 months of age, n = 21 KC;Sirt1-lox and 
n = 23 KC at 12 months of age. (C) Representative Alcian Blue staining in pancreas tissue sections of 12 month old animals. (D) Measurement 
of the percentage Alcian Blue positive area in pancreas tissue sections. n = 9–11. (E) Representative Ki67 immunohistochemistry in 
pancreas tissue sections of 12 month old animals. (F) Quantification of Ki67 positivity per image of lesion area. n = 9–13. All data are 
represented as mean +/− SEM, *P < 0.05.
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SIRT1 inhibitor CCAR2 was related to clinical outcomes. 
CCAR2 protein expression is very high in the majority 
of the samples (H-score > 200, Supplementary Figure S4) 
and correlated with improved survival; the 25% low 
CCAR2 expressing tumors corresponded to patients with 
poorer survival (Figure 4B). The low CCAR2 PDAC 
also independently correlated with undifferentiated and 
poorly differentiated tumors (n = 104, P < 0.01). Pathway 
analysis of the 88 genes that positively correlated with 
CCAR2 gene expression in microarray data of these 
human PDAC samples [21] resulted in ‘chromatin 
modification’, ‘histone acetylation’ and ‘cell cycle’ 
(Table 1, n = 104), supportive of a regulatory role of 
CCAR2 in typical SIRT1 activities in PDAC.
Then we assessed the clinical significance of 
increased epithelial proliferation and glycolysis gene 
expression, the latter confined to high cellularity samples 
(n = 78) to enrich for the epithelial gene expression. Higher 
percentage of Ki67-stained epithelium correlated with 
poor outcomes (Figure 4C). Also high SLC2A1/GLUT1, 
GAPDH and LDHA but not PKM2 correlated with worse 
patient survival (Figure 4D–4F and not shown).
In conclusion, CCAR2 protein but not SIRT1 is 
prognostic in PDAC. In addition, reduced patient survival 
time is seen in tumors that proliferate more and have 
higher expression of glycolysis genes.
DISCUSSION
SIRT1 has been attributed roles in tumor formation 
[7, 22–24] and is a regulator of metabolism, a process 
that interconnects with cancer [4, 25]. Previously we 
Figure 2: Expression of glycolytic proteins in murine SIRT1-deficient PanIN lesions. (A) Immunofluorescence for GLUT1 
(red) and (B) immunohistochemistry for HK2, GAPDH and PKM2 in pancreas tissue sections (bars = 50 micrometer).
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had shown a role of SIRT1 in metaplasia of pancreatic 
cells [14, 16]. Because of the link between glycolytic 
metabolism, tumor formation and tumor cell growth, 
we set out to explore whether these mechanisms were 
regulated by SIRT1 in the pancreas.
The development of pancreatic lesions is dependent 
on the activation of KRAS [15, 26, 27]. In the vast 
majority of PDAC patients, the KRAS gene presents an 
activating mutation [21]. Here we investigated the effects 
of SIRT1 inactivation in a KRAS mutant background 
Figure 3: Effects of SIRT1 siRNA in human PDAC cells. (A) Band density quantification by Image J analysis of Western Blot of 
SIRT1, acetylated and total p53 and p21, using B-ACTIN as a loading control, from Panc1 cells treated with a scrambled siRNA sequence 
or with siRNA for SIRT1. n = 6 (See representative Western Blot in Supplementary. Figure S3). (B) Real time RT-PCR analysis of the 
mRNA expression of SIRT1, GLUT1, HK2, GAPDH, PKM2, LDHA and PDK1 relative to HPRT as housekeeping gene (n = 4) in SIRT1 
siRNA treated Panc1 cells. (C) IncuCyte graph of the % increase in cell confluence in siRNA treated cells versus scr controls. One of three 
representative experiments is shown. All data are represented as mean +/− SEM, *P < 0.05, **P < 0.01, #P < 0.001.
Table 1: Reactome pathways enriched among the genes that positively correlated (Pearson and 
Spermann correlation coefficient ≥ 0.4) with CCAR2 in cDNA microarray analysis of PDAC (n = 104) 
#Term Corrected P-Value
Chromatin modifying enzymes 0, 0008
Chromatin organization 0, 0008
RNA transport 0, 0014
HATs acetylate histones 0, 0030
mRNA surveillance pathway 0, 0056
G2/M Transition 0, 0069
Mitotic G2-G2/M phases 0, 0069
Centrosome maturation 0, 0082
Recruitment of mitotic centrosome proteins and complexes 0, 0082
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using genetically engineered mice [15]. We are the first to 
demonstrate that a pancreas-specific inactivation of SIRT1 
limited the proliferation of early mucinous PanIN lesions. 
Similar to our observations, SIRT1-deficiency reduced 
polyp area and size in the APC+/min model of colorectal 
cancer [23] and reduced the number and the size of tumors 
in a colitis-induced colorectal cancer model [24]. We 
extended our findings on tumor development to tumor 
progression, where we also found that SIRT1 stimulated 
the proliferation of established pancreatic tumor cells, in 
line with previous reports (reviewed in [3]).
Aerobic glycolysis plays a central role in cellular 
transformation and the proliferation of tumors [18]. In 
PDAC, aerobic glycolysis is a source of intermediates for 
the non-oxidative pentose phosphate pathway [30] [31] . 
Our analyses demonstrated that SIRT1 positively regulated 
the expression of key genes in the glycolysis pathway. 
This new finding was made, both in the Kras mutant 
mouse model and in KRAS mutant human PDAC cells. A 
recent paper by Daemen et al [32] found that pancreatic 
tumor cell lines can be sub-typed according to their gene 
expression signature and metabolic profile with the quasi-
mesenchymal sub-type having a glycolytic nature. Our 
patient samples were categorized by this gene expression 
signature into exocrine, quasi-mesenchymal and classical 
subtype (as also reported in [33]) but did not show sub-
type specific differences in SIRT1 expression (not shown). 
Several genes may be mediating the SIRT1 
dependent regulation of glycolytic gene expression; SIRT1 
deacetylates and inactivates p53 which is a negatively 
regulator of glycolysis [13]. We detected consistent 
changes in acetylation of p53 upon manipulation of 
SIRT1 in a PDAC cell line. Despite our attempts, we did 
not succeed in detecting acetylated P53 in tissue sections 
of human PDAC. More in-depth study and suitable 
antibodies would be required to decipher if indeed p53 is 
the critical mediator. Other genes may be accountable such 
as MYC, a transcriptional activator of glycolysis genes, 
Figure 4: Correlation of SIRT1, CCAR2, Ki67 and glycolysis genes with PDAC patient survival outcomes. Kaplan Meier 
curves for the protein expression of SIRT1 (A) and CCAR2 (B) and Ki67 (C) scored in the tumor epithelium of PDAC patients (n = 104). 
Kaplan Meier curves of GLUT1 (D), GAPDH (E) and LDHA (F) gene expression in high cellularity patient samples (21) (n = 78).
Oncotarget7www.impactjournals.com/oncotarget
since SIRT1 is reported to increase MYC’s transcriptional 
program [19, 22]. Alternatively, SIRT1 protects HIF1a 
from acetylation and degradation and thereby can increase 
GLUT1 expression, a mechanism reported before [34]. 
Although not specific for SIRT1, HDAC inhibitors were 
found to down-regulate GLUT1 expression and to inhibit 
hexokinase 1 enzymatic activity in multiple myeloma 
cells [35], underscoring that acetylation plays a key role 
in regulation of glycolytic metabolism. The opposite 
regulation has also been reported, e.g. inhibition of SIRT1 
leads to acetylation and degradation of PKM2 while 
stimulating tumor proliferation [36]. Apart from glycolysis, 
other energy generating and biosynthetic pathways need 
to be controlled by the tumor cells in order to promote 
their cell proliferation [2–4]. SIRT1 deacetylates and 
thereby stimulates PGC1α. PGC1α is a negative regulator 
of glycolysis but promotes tumor progression through 
oxidative phosphorylation and lipogenesis [37] and by 
increasing mitochondrial gene expression that protects 
against pancreatic tumour cell apoptosis [38]. Therefore, 
SIRT1’s effect on PGC1α may also have contributed to 
our observations. We note that SIRT1 was reported to 
deacetylate KRAS thereby promoting its downstream 
signaling [39]. Knowing that oncogenic KRAS signaling 
upregulates many key enzymes in glycolysis (extensively 
reviewed in [40]), this may be another mechanism by 
which SIRT1 indirectly promotes glycolysis.
Despite the difference in area occupied by mucinous 
Alcian Blue positive lesions and the reduced expression of 
proteins in the glycolytic pathway, total area of lesions, as 
stained by Krt19 showed no differences between controls 
and SIRT1 deficient mice. Our observation suggests that 
only the early PanIN stage is affected in the SIRT1 loss of 
function model. We speculate that a subset of cells have 
started to compensate for the lower proliferation/reduced 
glycolysis of the early PanIN lesions. These cells must 
have progressed faster or have skipped the early PanIN 
stage. It has been reported that pancreatic tumor cells, 
upon genetic or pharmacological ablation of the bulk of 
glycolysis-dependent cells can become more aggressive 
and can lead to full recurrence of the tumor. This involves 
the acquisition of stem cell features and metabolic 
reprogramming with a shift from glycolysis to oxidative 
phosphorylation and is notably dependent on PCG1a [28], 
a protein well known for its regulation by SIRT1 [29], and 
important in tumor growth, as outlined above.
We verified the significance of our findings in 
clinical samples. In a cohort of human early stage tumors, 
high proliferation and high expression of glycolysis 
genes corresponded, not unexpectedly, to poorer patient 
outcomes. This inferred that high expression of SIRT1 
might also lead to worse outcome. However, expression 
of SIRT1 in our analysis did not directly correlate with 
the patient survival outcomes, in discrepancy with other 
studies reporting that SIRT1 in PDAC correlated with 
poor histological differentiation and poor postsurgical 
survival [41] and with increased size, lymph node burden 
and hepatic metastasis [20]. Nevertheless, we found that 
CCAR2, an inhibitor of SIRT1’s deacetylase activity, 
was prognostic in our cohort, with the lower CCAR2 
expressing tumors corresponding to poorly differentiated 
high mortality tumors. Based on literature [11, 42], the 
lowest CCAR2 expressing tumors would have the highest 
SIRT1 activity. Microarray data analysis of the patient 
samples also further suggested that CCAR2 regulates 
typical SIRT1 activities such as histone deacetylation but 
more research and the development of suitable antibodies 
would be needed before CCAR2 could be definitely used 
as a surrogate marker of low SIRT1 activity. Indeed, 
CCAR2 may also exert other effects independent of 
SIRT1 inhibition; for example, a recent report showed 
that CCAR2 is a tumor suppressor that stabilizes p53 with 
effects independent of SIRT1 [43].
In conclusion, our new results underscore a novel 
oncogenic function of SIRT1 during pancreatic cancer 
development where it stimulates the proliferation and 
expression of glycolytic proteins. SIRT1 is an interesting 
druggable target to halt tumor cell proliferation with 
successes in chronic myeloid leukemia [44] and with 
an inhibitor found to be safe in a clinical trial [45, 46]. 
Several groups have found promising effects of SIRT1 
drugs in preclinical models of PDAC [3]. Our data do not 
only reinforce the idea to explore SIRT1 as a druggable 
target in early stage pancreatic cancer, we also deciphered 
a relation with tumor metabolism. We found that SIRT1 is 
a stimulus for glycolytic enzymes. Interestingly, specific 
drugs for these glycolytic enzymes are currently being 
tested, e.g. the LDH-A antagonist FX11 in PDAC [47] or 
the Hexokinase II inhibitor, 3-BrPA in breast cancer [48]. 
One could envision a combination therapy of a SIRT1 
inhibitor and one of these drugs that target the metabolism 
of the pancreatic tumor or one could potentially use low 
CCAR2 expression, likely corresponding to high SIRT1 
activity, as a biomarker to select a population of early 
stage PDAC patients for therapy with drugs that target 
the glycolytic metabolism. Our study paves the way for 
further investigation into these new therapeutic angles.
MATERIALS AND METHODS
Animals and in vivo experimentation
B6;129-Sirt1tm1Ygu/J (Sirt1-lox) strains were obtained 
from Jackson Laboratories and bred with the B6.FVB-
Tg(Ipf1-cre)6Tuv/J (Pdx1-Cre, abbreviated as C) [15] 
and the lox-STOP-lox-KrasG12D line (abbreviated as KC) 
[15] to create KC;Sirt1-lox mice. The Sirt1-lox mice [49] 
have a loxP-flanked neomycin cassette just upstream of 
exon 4, and a third loxP site just downstream of exon 4 
(encoding a conserved Sirt1 motif) of the targeted gene. 
The resulting offspring have exon 4 deleted in the pancreas. 
In all experiments, only homozygous Sirt1-lox mice were 
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analyzed and the respective Sirt1 wild-type line was used 
as control. All animal experiments were approved by the 
Garvan Animal Ethical Committee (AEC approval #12-52).
Patient derived tissue collection
Biospecimens (tissue microarrays of paraffin 
embedded material and microarray gene expression 
datasets) and the clinico-pathological data were provided 
by the Australian Pancreatic Cancer Genome Initiative 
(APGI) [21, 50, 51] (ethical approval:HREC/11/
RPAH/329 – The Molecular Pathology of Pancreatic 
Cancer, incorporating the APGI, approved by Sydney 
Local Health District –RPA Zone, protocol x11-0220).
Immunostaining
Mouse pancreas tissues were fixed in 4% formalin 
and embedded in paraffin. All immunohistochemistry 
was performed using the Dako Autostainer, Universal 
Staining System Model# LV-1 and the Leica BOND RX, 
according to supplier procedures. After deparaffinization 
and antigen retrieval (S1699 Target Retrieval Solution, 
Dako), slides were incubated with diluted primary 
antibody (Supplementary. Table S1) for 60 minutes and 
a secondary EnVision antibody (Dako) (Supplementary. 
Table S1) for 30 minutes. Finally the slides were treated 
with 3,3′-Diaminobenzidine (DAB+ Substrate Chrmogen 
system, Dako) for 10 minutes and counterstained with 
haematoxylin. All immunohistochemistry images were 
taken using the Aperio Scanscope CS system (Leica 
Biosystems). For immunofluorescence of GLUT-1, 
mouse pancreas was treated with EDTA-NaOH antigen 
retrieval (boiling 20 minutes in 1 mM pH 8). Sections 
were incubated with primary antibody overnight at 
4°C and subsequently with anti-mouse-594, DBA and 
Dapi. Sections were viewed on a Nikon Eclipse TE300 
epifluorescence microscope (Nikon Instruments Inc, 
Melville, NY) equipped with a DS-5M Standard charge-
coupled device camera (Nikon Instruments Inc) and 
acquired with NISElements (Nikon Instruments Inc).
Human PDAC samples were assembled by APGI 
into tissue microarrays containing 3 samples of each 
patient tumor. SIRT1 and CCAR2 immunohistochemistry 
(IHC) on the human tissue microarrays was performed 
as reported before [14] and was scored blindly as 
absolute intensity (arbitrary values 0–3) and an estimated 
percentage of positive nuclei (H-score).
Alcian blue staining
Tissue slides were manually stained with Clinipure 
ALCBLUE1 03 (1% alcian blue, 3% acetic acid solution) 
for 30 minutes and counterstained with eosin. Alcian Blue 
quantification was performed by analyzing the stained 
slides with the Leica DM6000 Power Mosaic microscope 
and software. Twenty-five pictures per sample were 
manually selected to discard any images with empty 
areas or non-pancreatic tissue like lymphoid tissue, 
blood vessels or fat. The stained area was measured and 
the percentage of stained area over total tissue area was 
calculated.
siRNA knockdown of SIRT1
Panc-1 cells were obtained from the American Type 
Culture Collection (ATCC) Cell Biology Collection and 
used within 6 months of revival. The cells were tested 
for Mycoplasma contamination. The cells were plated in 
DMEM +10% Fetal Bovine Serum. At 24 hours, cells were 
transfected with 10 nM siRNA / Hyperfect complexes 
according to the manufacturers instructions (Qiagen) and 
incubated 37C, 5% CO2. One of two successful siRNAs 
(Invitrogen) was used for further analysis. Panc1 seeded 
in 96 well plates at 2 × 103 cells were monitored for 
growth (percent confluence) for up to 5 days following 
siRNA treatment using the IncuCyteZOOM live cell 
imager (Essen Bioscience). Replicate plates were also 
analysed for cell proliferation via BRDU ELISA (Roche, 
11647229001) with a 2 hour Bromodeoxyuridine pulse at 
96 hours per manufacturers instructions.
Western blotting 
Cells were lysed in Normal Lysis Buffer (Hepes 
50 mM, NaCl 150 mM, Glycerol 10%, Triton X100 1%, 
MgCl2 1.5 mM, EGTA 1 mM, Pyrophosphate 10 mM, NaF 
100 mM) complemented with protease and phosphatase 
inhibitors (Roche) and MG132 (10 ug/ml). Frozen tissue 
specimens were homogenized in RIPA Buffer (Tris-Hcl 
50 mM, NaCl 150 mM, EDTA 5 mM, NP40 0.5%, 0.1%, 
SDS 0.1%) complemented with protease and phosphatase 
inhibitors and MG132. Protein extracts were subjected to 
electrophoresis on 4–12% gradient polyacrylamide gels 
(SDS-PAGE) and transferred onto a PVDF membrane 
(Biorad). The membrane was incubated overnight at 4°C 
with primary antibodies (Supplementary. Table S1) diluted 
in TBS/BSA (Tris pH 7.4 10 mM, NaCl 150 mM, 5% BSA, 
0.05% Sodium Azide and phenol red). The membrane was 
then incubated with HRP-conjugated secondary antibodies 
at a 1/2000 dilution. The signals were visualized with ECL 
(Perkin Elmer) and autoradiography, and band densities of 
the gene of interest relative to the housekeeping gene were 
measured with ImageJ software.
Real time PCR analysis
 Total RNA from Panc1 cells was isolated using 
the Purelink RNA mini kit (Ambion, Life Technologies) 
and subjected to DNase1 treatment (Ambion, Life 
Technologies). First strand cDNA synthesis was 
performed with a random hexamer / poly-A primer mix 
(Roche) according to manufacturers instructions. Real 
Oncotarget9www.impactjournals.com/oncotarget
time PCR products were amplified with Fast Start SYBR 
Green (Roche) using the primers listed in Supplementary. 
Table S2 using the 7900HT Fast Real Time PCR System 
(Applied Biosystems). PCR product specificity was 
confirmed with dissociation curve analysis and 2% agarose 
gel electrophoresis of products. Expression levels were 
normalized to house keeping gene expression (HPRT).
Statistics
Results are presented as mean ± SEM. The number 
of independent experiments is represented as n. Data were 
analyzed by Prism 6.0 using Student t test (unpaired t test) 
or two-way ANOVA and results considered significant 
when P < 0.05.
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